Art

J-GLOBAL ID：201802230125974535   Reference number：18A0907245

Survival benefit of cabazitaxel in castration-resistant prostate cancer patients predicted with poor prognosis

予後不良が予測される去勢抵抗性前立腺癌の患者におけるカバジタキセルの生存利益

Author (18)： HASHIMOTO Kohei (Sapporo Medical Univ., Sapporo, JPN) ,  HASHIMOTO Kohei (Sapporo Medical Univ. Urologic Oncology Consortium) ,  TANAKA Toshiaki (Sapporo Medical Univ., Sapporo, JPN) ,  TANAKA Toshiaki (Sapporo Medical Univ. Urologic Oncology Consortium) ,  TABATA Hidetoshi (Sapporo Medical Univ., Sapporo, JPN) ,  TAKAYANAGI Akio (Sapporo Medical Univ., Sapporo, JPN) ,  SHINDO Tetsuya (Sapporo Medical Univ., Sapporo, JPN) ,  SHINDO Tetsuya (Sapporo Medical Univ. Urologic Oncology Consortium) ,  YAMAMOTO Takanobu (Sapporo Medical Univ., Sapporo, JPN) ,  SHIBAMORI Kosuke (Sapporo Medical Univ., Sapporo, JPN) ,  KATO Shuichi (Sapporo Medical Univ., Sapporo, JPN) ,  HASHIMOTO Jiro (Sapporo Medical Univ., Sapporo, JPN) ,  INOUE Ryuta (Sapporo Medical Univ., Sapporo, JPN) ,  MURANAKA Takashi (Sapporo Medical Univ., Sapporo, JPN) ,  TAKAHASHI Atsushi (Hakodate Goryokaku Hospital) ,  TAKAHASHI Atsushi (Sapporo Medical Univ. Urologic Oncology Consortium) ,  MASUMORI Naoya (Sapporo Medical Univ., Sapporo, JPN) ,  MASUMORI Naoya (Sapporo Medical Univ. Urologic Oncology Consortium)
Material： 日本泌尿器科学会総会(Web)
Volume： 106th  Page： ROMBUNNO.IS-29 (WEB ONLY)  Publication year： 2018 
JST Material Number： U1003A  Document type： Proceedings
Article type： 会議録記事  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *castration-resistant prostate cancer ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0907245&from=J-GLOBAL&jstjournalNo=U1003A") }}

JST classification (2)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (2)： Cabazitaxel ,  Docetaxel

Terms in the title (7)： 予後不良 ,  予測 ,  去勢抵抗性前立腺癌 ,  患者 ,  カバジタキセル ,  生存 ,  利益